Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

698

Participants

Timeline

Start Date

April 18, 2014

Primary Completion Date

March 11, 2015

Study Completion Date

March 11, 2015

Conditions
AbscessWound InfectionSurgical Site InfectionCellulitis
Interventions
DRUG

Dalbavancin

Dalbavancin IV infusion over 30 minutes.

DRUG

Dalbavancin-matching Placebo

Dalbavancin-matching placebo IV infusion over 30 minutes.

Trial Locations (78)

1000

802, Sofia

1055

751, Middleburg

1431

800, Sofia

1606

801, Sofia

2113

755, Johannesburg

2330

756, Breyten

3000

752, Dundee

4012

352, Debrecen

4600

302, Kutaisi

6014

758, Port Elizabeth

6720

351, Szeged

6850

754, Worcester

7400

353, Kaposvár

7530

760, Cape Town

7632

354, Pécs

10000

200, Zagreb

201, Zagreb

10318

253, Tallinn

11000

600, Belgrade

601, Belgrade

13419

252, Tallinn

18000

603, Niš

18009

700, Cherkasy

20037

112, Washington D.C.

21000

602, Novi Sad

30909

114, Augusta

31405

125, Savannah

31904

122, Columbus

32806

107, Orlando

34769

120, Saint Cloud

36106

110, Montgomery

37064

126, Franklin

37167

127, Smyrna

42122

503, Bucharest

43608

111, Toledo

48202

109, Detroit

49005

704, Dnipropetrovsk

51014

251, Tartu

59701

121, Butte

61037

705, Kharkiv

68131

123, Omaha

69032

702, Zaporizhzhya

70535

119, Eunice

76012

706, Ivano-Frankivsk

76025

701, Ivano-Frankivsk

79059

703, Lviv

90806

117, Long Beach

90813

106, Long Beach

91342

105, Sylmar

92120

104, San Diego

113, San Diego

115, San Diego

116, San Diego

92804

103, Anaheim

95204

108, Stockton

95350

118, Modesto

111539

552, Moscow

554, Moscow

188643

555, Vsevolozhsk

198099

551, Saint Petersburg

400006

501, Cluj-Napoca

630051

553, Novosibirsk

634063

556, Tomsk

664079

557, Irkutsk

01199

101, Springfield

0144

303, Tbilisi

0160

300, Tbilisi

301, Tbilisi

LV-5417

402, Daugavpils

LV-3414

401, Liepāja

LV-4601

403, Rēzekne

LV-1002

400, Riga

LV-1038

404, Riga

030303

502, Bucharest

041915

500, Bucharest

0040

757, Pretoria

0084

753, Pretoria

0183

759, Pretoria

All Listed Sponsors
lead

Durata Therapeutics Inc., an affiliate of Allergan plc

INDUSTRY

NCT02127970 - Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter